Safety of Interferon Gamma-1b With Rituximab in Non-Hodgkin's Lymphoma Patients
Status:
Terminated
Trial end date:
2004-06-01
Target enrollment:
Participant gender:
Summary
Evaluate the safety and efficacy of the dosing schedule of subcutaneous interferon gamma-1b
(IFN g-1b) administered 3 times per week with Rituximab for 4 weeks, in patients with
progressive or relapsed low-grade Non-Hodgkin's Lymphoma (NHL)
International study with sites in the Czech Republic and Poland